BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference

CRESSKILL, N.J. and JERUSALEM, July 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021. The Company will also host one-on-one investor meetings at the conference.

Presentation details can be found below.

About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:Scott Areglado SVP and Chief Financial Officer617-771-2287[email protected] 

Investors:Bob YedidLifeSci Advisors646-597-6989[email protected]        

You May Also Be Interested In

• Bahia Metals Files NI 43-101 Technical Report for Initial 313 Million Tonne Mangueiros Main Inferred Mineral Resource Estimate
• Russo's New York Pizzeria Opens Second Arizona Location in Tempe
• Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act